Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789633 · ClinicalTrials.gov registry record · Phase 3
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by AB Science.
- Completed
- Registry status
- Phase 3
- Development phase
- 353
- Enrollment target
NCT00789633 is a Phase 3 study that has completed, run by AB Science. The registered enrollment target is 353 participants.
The verdict
NCT00789633, a Phase 3 study, has completed, sponsored by AB Science.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 353 participants
- Enrollment target
Study Summary
The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG Masitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2008-11-25 |
| Est. Completion | 2012-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789633
The ClinicalTrials.gov registry entry for NCT00789633 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AB Science, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00789633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00789633 about?
NCT00789633 is a clinical study titled "Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer". The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.
What is the current status of trial NCT00789633?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 353 participants. The study started on 2008-11-25. Estimated completion is 2012-08-31.
What interventions are being tested in trial NCT00789633?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), Masitinib (DRUG).
Who is sponsoring clinical trial NCT00789633?
This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.